Free Trial

Fusion Antibodies (FAB) Competitors

Fusion Antibodies logo
GBX 6.90 +0.05 (+0.73%)
As of 12:30 PM Eastern

FAB vs. SAR, AOR, OPTI, AREC, IMM, POLB, RLM, NSCI, SNG, and IXI

Should you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include Sareum (SAR), AorTech International (AOR), OptiBiotix Health (OPTI), Arecor Therapeutics (AREC), ImmuPharma (IMM), Poolbeg Pharma (POLB), Realm Therapeutics (RLM), NetScientific (NSCI), Synairgen (SNG), and IXICO (IXI). These companies are all part of the "biotechnology" industry.

Fusion Antibodies vs.

Fusion Antibodies (LON:FAB) and Sareum (LON:SAR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.

Sareum received 28 more outperform votes than Fusion Antibodies when rated by MarketBeat users. However, 68.35% of users gave Fusion Antibodies an outperform vote while only 66.13% of users gave Sareum an outperform vote.

CompanyUnderperformOutperform
Fusion AntibodiesOutperform Votes
54
68.35%
Underperform Votes
25
31.65%
SareumOutperform Votes
82
66.13%
Underperform Votes
42
33.87%

Fusion Antibodies has higher revenue and earnings than Sareum. Sareum is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£2.09M3.10-£4.10M-£4.45-1.55
SareumN/AN/A-£5.28M-£4.22-3.55

Sareum has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Fusion Antibodies' return on equity of -137.11% beat Sareum's return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-195.95% -137.11% -63.78%
Sareum N/A -270.25%-113.80%

21.0% of Fusion Antibodies shares are owned by institutional investors. 11.4% of Fusion Antibodies shares are owned by company insiders. Comparatively, 5.0% of Sareum shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Fusion Antibodies has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Sareum has a beta of -1.08, suggesting that its stock price is 208% less volatile than the S&P 500.

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Sareum'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
Sareum Neutral

Summary

Fusion Antibodies beats Sareum on 9 of the 12 factors compared between the two stocks.

Get Fusion Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FAB vs. The Competition

MetricFusion AntibodiesBiotechnology IndustryMedical SectorLON Exchange
Market Cap£6.49M£128.97M£5.33B£2.62B
Dividend YieldN/A3.74%5.20%5.05%
P/E Ratio-1.553.4226.72134.60
Price / Sales3.104,168.72395.56221,328.11
Price / Cash9.0213.1938.3228.03
Price / Book1.9633.216.763.84
Net Income-£4.10M-£91.56M£3.23B£5.88B
7 Day Performance2.99%3.50%0.41%3.54%
1 Month PerformanceN/A7.75%9.12%25.38%
1 Year Performance89.04%102.80%18.74%130.62%

Fusion Antibodies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FAB
Fusion Antibodies
N/AGBX 6.90
+0.7%
N/A+91.0%£6.49M£2.09M-1.5548Gap Up
SAR
Sareum
N/AGBX 16.25
-9.7%
N/A-52.6%£20.30MN/A-3.853,211Gap Down
AOR
AorTech International
N/AN/AN/AN/A£19.99M£539,000.00-33.383
OPTI
OptiBiotix Health
N/AGBX 19
+5.6%
N/A-2.5%£18.61M£590,009.23-6.011News Coverage
AREC
Arecor Therapeutics
N/AGBX 41.18
+0.4%
N/A-72.6%£15.55M£6.04M-1.4610News Coverage
Insider Trade
Gap Up
IMM
ImmuPharma
N/AGBX 3.53
+4.6%
N/A+19.3%£14.99M£-71,310.29-6.0913Earnings Report
POLB
Poolbeg Pharma
N/AGBX 2.90
+1.8%
N/A-80.5%£14.91MN/A0.0012News Coverage
Earnings Report
Gap Down
RLM
Realm Therapeutics
N/AN/AN/AN/A£13.41M£501,919.00-0.66N/A
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45M-486.3626
SNG
Synairgen
N/AN/AN/AN/A£9.04MN/A-0.5634Gap Down
IXI
IXICO
N/AGBX 9.03
-2.4%
N/A+55.2%£8.36M£11.50M-2.3489Earnings Report
Gap Down

Related Companies and Tools


This page (LON:FAB) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners